[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-human-papillomavirus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-human-papillomavirus-infection":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639976","phase-2-a-study-of-the-preliminary-efficacy-of-dare-hpv-to-treat-high-risk-persistent-human-papillomavirus-hrhpv-100639976",false,"NCT07601074","A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)","A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection","Inclusion Criteria:\n\n1. Provision of written informed consent prior to any study-specific procedures.\n2. Premenopausal women aged 22-50 years inclusive at the time of screening visit.\n3. Positive result for genital hrHPV (types 16, 18, or 'other') on at least 2 tests over the span of at least 12 months (history of persistent hrHPV infection for at least 12 months), based on review of participant's medical records. The visit 1 screening genital hrHPV test may be the second positive test.\n4. Generally, in good health with no clinically significant disease as determined by the Investigator.\n5. Regular menstrual cycle with an approximate 28-day cycle OR women who are amenorrheic due to effective contraception (such as levonorgestrel intrauterine system, or continuous oral contraception).\n6. Agree to refrain from vaginal douching, insertion of intravaginal devices (e.g., tampons, menstrual cups), and use of condoms for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.\n7. Agree to abstain from all vaginal and oral intercourse for at least 48 hours before the first dose of study drug through at least 72 hours after the last dose of study drug.\n8. Women at risk of pregnancy must use a highly effective form of birth control (confirmed by the Investigator) for the entire duration of the study. Rhythm methods and consistent use of condoms will not be considered as highly effective methods of birth control. Highly effective forms of birth control include:\n\n   * Heterosexual abstinence\n   * Vasectomized male partner (provided that the male partner is the sole sexual partner of the female participant with childbearing potential and that the vasectomized partner has received medical assessment of the surgical success);\n   * Oral or transdermal combined ethinyl estradiol\u002Fprogestin hormonal contraception associated with inhibition of ovulation;\n   * Oral, injectable or implantable progestogen-only hormone contraception associated with inhibition of ovulation (e.g., Depo-Provera™, Nexplanon, Slynd);\n   * Any effective copper intrauterine device\u002Flevonorgestrel intrauterine system;\n   * Female sterilization by tubal occlusion or bilateral salpingectomy;\n   * Supracervical hysterectomy.\n9. Ability and willingness to attend the necessary visits to the study center.\n10. Ability to comprehend all study related documentation, including written informed consent form, and complete all study-related tasks including daily diary.\n11. Be willing and able to adhere to the prohibitions and restrictions specified in the protocol.\n\nExclusion Criteria:\n\n1. Any significant disease or disorder (e.g., cardiovascular, pulmonary, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study.\n2. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening and at baseline, which in the opinion of the Investigator, may put the participant at risk because of her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.\n3. Cytological abnormality of the uterine cervix defined as LSIL or mild cervical intraepithelial neoplasia (CIN1), or HSIL or moderate (CIN 2) or severe (CIN 3) histology, as proven by cytology or colposcopic biopsy collected within the 12 months prior to screening or cytology at screening.\n4. Pregnant, breastfeeding, or lactating women (WOCBP must have a negative urine pregnancy test at screening and at the start of treatment \\[i.e., Day 1\\]).\n5. Active pelvic infection (positive for gonorrhea or chlamydial infection, positive test and symptoms for bacterial vaginosis, candida vaginitis or trichomonal vaginitis). Participants with positive results can be treated and re-tested once during screening.\n6. Positive result for hepatitis B, hepatitis C antibody or human immunodeficiency virus.\n7. Currently taking systemic immunosuppressants, biologics, intra-vaginal preparations, or any prescription that in the opinion of the Investigator could be a potential safety issue or interfere with the interpretation of the results.\n8. Previous exposure to lopinavir\u002Fritonavir (within 3 months prior to screening), contraindication to the use of lopinavir\u002Fritonavir or known allergy, hypersensitivity, or intolerance to any component of lopinavir\u002Fritonavir excipients.\n9. Recent history (within 3 months prior to screening) of Stevens-Johnson syndrome, erythema multiforme, urticaria, or angioedema.\n10. Receipt of any investigational product within 30 days or 5 half-lives prior to dosing.\n11. Participants who, in the opinion of the Investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular, the study restrictions and risks involved).","FEMALE","22 Years","50 Years",{"count":20,"type":21},118,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.\n\nThe study will look at two different doses of DARE-HPV and two different treatment durations of 14 and 21 days compared to a placebo group or 14 or 21 days of treatment.",[27,28],"Human Papilloma Virus (HPV)","High-risk Human Papillomavirus Infection",[30,31],"HPV","hrHPV","NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":21},"2026-06",{"date":40,"type":21},"2027-12",{"name":42,"class":43},"Daré Bioscience, Inc.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":44},"100509828","observational-study-of-viral-biomarkers-and-micrornas-in-tumors-orofarynx-and-occult-tumors-positive-for-papilloma-virus-100509828","NCT05918510","Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus","Inclusion Criteria:\n\n* Squamous cell carcinomas of the oropharynx and occult neoplasms with lymph node metastases laterocervical cytologically positive for squamous cell carcinoma treated with TORS or RT or RT\u002FCT\n* Age \\> 18 years\n* ECOG performance status \\\u003C\\_ 2\n* Ability to follow study procedures and complete questionnaires\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Presence of distant metastases at the time of diagnosis\n* Previous cancer of the head and neck district\n* Second tumor in therapy or follow-up for less than 5 years","ALL","18 Years",{"count":54,"type":21},142,"OBSERVATIONAL","Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids of these patients, may have important prognostic and diagnostic value not only in HPV-related OPSCCs but also in HPV+ occult T. Accordingly, this study aims to aim to better characterize their potential as biomarkers and to detect the possibility of their their use to implement the sensitivity and specificity of radiological methodologies (PET-CT and MRI), already in use in clinical practice, for monitoring disease progression in this specific subgroup. Finally, by using the collected material to generate organoids and Patient Derived Xenograft (PDX), the study also aims to identify possible new molecular drugs, which could solve the problem of resistance to radiochemotherapy.",[58,59,28,60,61,62],"Squamous Cell Carcinoma of the Oropharynx","Carcinomas of Unknown Primary Site","Liquid Biopsy","Lymph Node Metastasis","Occult Tumor of the Head and Neck Area",[64,65,66,67],"Oropharyngeal Tumor","Occult Cancer","HPV Infection","head-neck area","RECRUITING","2023-10-06",{"date":71,"type":36},"2023-10-10",{"date":73,"type":36},"2022-04-04",{"date":75,"type":21},"2029-04-04",{"name":77,"class":78},"Regina Elena Cancer Institute","OTHER","High Risk Human Papillomavirus Infection"]